Progress Toward Blood Test for Down Syndrome
Study Shows Blood Test May Allow Pregnant Women to Avoid Invasive Prenatal Screening Tests
Jan. 11, 2011 -- A new blood test may help pregnant women who are at high risk for having a baby with Down syndrome avoid more invasive tests such as amniocentesis and chronic villus sampling (CVS).
The blood test analyzes components of genetic material from both the pregnant woman and her fetus that is present in the mother’s blood. It could help avoid up to 98% of these screening procedures, according to the study, which appears in BMJ.
While amniocentesis and CVS can help definitively determine if an unborn baby has Down syndrome or trisomy 21, these tests do carry a risk of miscarriage, and some women are unwilling to take this risk. These tests also screen for other less common fetal abnormalities and birth defects such as trisomy 13 and trisomy 18.
Accuracy of Blood Test
The new blood test would be used if a woman was considered at high risk for having a child with Down syndrome based on her age or other factors. “The sequencing test could be used to rule out trisomy 21 among high-risk pregnancies before proceeding to invasive diagnostic testing to reduce the number of cases requiring amniocentesis or CVS,” conclude study authors who were led by Dennis Lo of the Chinese University of Hong Kong in China.
The new study included 753 pregnant women who were at high risk for having a child with Down syndrome. Of these, 86 women were determined to be pregnant with a child with Down syndrome.
There were no false-negative results with the new test, suggesting it can help avoid 98% of follow-up invasive tests in women whose test shows that their baby does not have Down syndrome.
“In a year or two, this test may be available, but it won’t replace existing technologies, it will nudge its way into our armamentarium of available methodologies,” says Mark I. Evans, MD, director of Comprehensive Genetics in New York City, and an obstetrician/gynecologist at Mount Sinai School of Medicine, also in New York City.
‘Not Ready for Prime Time’
“The bad news is that prenatal diagnosis is not just about Down syndrome,” he says. “Down syndrome represents about 50% of what we find, and this new test can help with that, but it may also give women a false sense of reassurance.”
Still, he adds, “it’s an important step forward.”
The technology is likely prohibitively expensive and time-consuming at this point, he says.
“It’s not ready for prime time, but researchers are actively working on methods to increase its efficiency,” he says.
“Patients are very concerned about loss rates with aminocentesis and CVS and want reassurance about their pregnancies, so we are always looking for a better test,” says Jennifer Wu, an obstetrician/gynecologist Lenox Hill Hospital in New York City. “This test looks very promising, but it is also very expensive,”